• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688236.SS
Share

Beijing Chunlizhengda Medical Instruments Co., Ltd. Stocks

CN¥ 15.62Last Updated 16.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 835.34M

CN¥ 15.62
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Chunlizhengda Medical Instruments Co., Ltd. operates as a specialist in orthopedic medical devices. Its core activities encompass the development, manufacturing, and marketing of surgical implants, instruments, and related medical supplies. While primarily focused on the People's Republic of China, its product portfolio prominently features implantable orthopedic solutions, particularly artificial joint prostheses and spinal systems. The company distributes its offerings mainly through a network of channel partners, engages in ODM/OEM collaborations, and supplies hospitals directly, all under its established Chunli brand. Additionally, Beijing Chunlizhengda extends its reach by exporting products to various international markets. Established in 1998, the firm maintains its headquarters in Beijing, China.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 15:20

TSMC's profits hit a record high for the fifth consecutive quarter. Is the "AI megatrend" continuing?

16.07.2026 15:00

IPO Standard Nuclear: A developer of nuclear reactor fuel has gone public

16.07.2026 14:59

Csquare IPO: Shares of the data center provider are now available

16.07.2026 14:27

Shares of a small-cap psychedelic drug developer have soared. Eli Lilly may acquire the company.

16.07.2026 13:00

"Weeks, not months": The IEA warned of the threat of a global crisis over the Strait of Hormuz

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026